http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 11 Aug 2026 05:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended <chron>June 30, 2026</chron> and provide a business update.</p> <p>The English session of the conference call will be held at <chron>8:00 PM</chron> on <chron>August 26, 2026</chron>, <person>Beijing Time</person> (<chron>8:00 AM</chron> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Eastern Time on <chron>August 26, 2026</chron>), and the Mandarin session of the conference call will be held at <chron>9:00 AM</chron> <person>Beijing http://www.streetinsider.com/PRNewswire/Insilico+Medicine+Announces+2026+Interim+Earnings+Conference+Call+Dates/26900243.html Tue, 11 Aug 2026 05:45:00 -0400 3696 A.50216935 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/Press+Releases/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html <div class="xn-content"> <ul type="disc"><li>As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.</li><li>ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.</li><li>In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.</li><li>Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both http://www.streetinsider.com/PRNewswire/AI-empowered+Pipeline-in-a-drug+Option%3A+Insilico+Medicine+Nominates+ISM9077%2C+Potential+First-in-class+Target+Y+Inhibitor%2C+as+Preclinical+Candidate+%28PCC%29+for+Ocular+Diseases%2C+Inflammatory+Disorders+and/26876565.html Wed, 05 Aug 2026 20:30:00 -0400 3696 A.11003533 A.50210275 A.50216935 O.24152401 O.31525930 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Launches+the+Industry%27s+First+Drug+Discovery+and+Development+%28DDD%29+Benchmark+as+a+Service%2C+to+Evaluate+Frontier+AI+and+Foundation+Models+on+Real-World+Science/26840110.html <div class="xn-content"> <p><i>Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard.</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- As general-purpose and domain-specific AI models rapidly infiltrate drug discovery, one critical question looms over the pharmaceutical sector: <b><i>Can these models actually discover drugs, or are they just good at taking tests?</i></b> Today, most publicly available AI benchmarks suffer from severe data contamination, where models achieve artificially inflated scores simply by memorizing test questions present in their training http://www.streetinsider.com/Press+Releases/Insilico+Medicine+Launches+the+Industry%27s+First+Drug+Discovery+and+Development+%28DDD%29+Benchmark+as+a+Service%2C+to+Evaluate+Frontier+AI+and+Foundation+Models+on+Real-World+Science/26840110.html Thu, 30 Jul 2026 09:00:00 -0400 3696 A.50216935 O.57690994 O15